BR0308146A - Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto - Google Patents
Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um compostoInfo
- Publication number
- BR0308146A BR0308146A BR0308146-0A BR0308146A BR0308146A BR 0308146 A BR0308146 A BR 0308146A BR 0308146 A BR0308146 A BR 0308146A BR 0308146 A BR0308146 A BR 0308146A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- hydroxy
- hydrogen
- halo
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- -1 Heterocyclic amides Chemical class 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 102000007390 Glycogen Phosphorylase Human genes 0.000 abstract 2
- 108010046163 Glycogen Phosphorylase Proteins 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0205165.4A GB0205165D0 (en) | 2002-03-06 | 2002-03-06 | Chemical compounds |
| PCT/GB2003/000877 WO2003074532A1 (en) | 2002-03-06 | 2003-03-04 | Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308146A true BR0308146A (pt) | 2004-12-07 |
Family
ID=9932329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308146-0A BR0308146A (pt) | 2002-03-06 | 2003-03-04 | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7129249B2 (enExample) |
| EP (1) | EP1483270A1 (enExample) |
| JP (1) | JP2005526058A (enExample) |
| KR (1) | KR20040096661A (enExample) |
| CN (1) | CN100384852C (enExample) |
| AR (1) | AR038888A1 (enExample) |
| AU (1) | AU2003214377A1 (enExample) |
| BR (1) | BR0308146A (enExample) |
| CA (1) | CA2477667A1 (enExample) |
| GB (1) | GB0205165D0 (enExample) |
| IL (1) | IL163803A0 (enExample) |
| MX (1) | MXPA04008614A (enExample) |
| NO (1) | NO20043852L (enExample) |
| NZ (1) | NZ534990A (enExample) |
| PL (1) | PL372973A1 (enExample) |
| TW (1) | TW200305412A (enExample) |
| WO (1) | WO2003074532A1 (enExample) |
| ZA (1) | ZA200406679B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| DK1537078T3 (da) * | 2002-08-29 | 2010-08-02 | Merck Sharp & Dohme | Indoler med anti-diabetisk aktivitet |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0320422D0 (en) * | 2003-08-30 | 2003-10-01 | Astrazeneca Ab | Chemical compounds |
| CA2551952A1 (en) | 2003-12-29 | 2005-07-21 | Sepracor Inc. | Pyrrole and pyrazole daao inhibitors |
| DE102004004971B3 (de) * | 2004-01-31 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel |
| US7470706B2 (en) | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| US7498341B2 (en) * | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| ATE438645T1 (de) * | 2004-01-31 | 2009-08-15 | Sanofi Aventis Deutschland | 7-phenylamino-4-chinolon-3-carbonsäure-derivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US7402674B2 (en) | 2004-01-31 | 2008-07-22 | Sanofi-Aventis Deutschland Gmbh, | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| WO2006055462A1 (en) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7214704B2 (en) | 2004-11-15 | 2007-05-08 | Bristol-Myers Squibb Company | 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| WO2006055463A2 (en) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7314882B2 (en) | 2005-01-12 | 2008-01-01 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| DE102005063244A1 (de) * | 2005-12-21 | 2007-06-28 | Eberhard-Karls-Universität Tübingen | Modifiziertes 2-Nitroimidazol-Derivat |
| CA2636324C (en) | 2006-01-06 | 2012-03-20 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| WO2007081542A2 (en) | 2006-01-06 | 2007-07-19 | Sepracor Inc. | Tetralone-based monoamine reuptake inhibitors |
| US20090312559A1 (en) * | 2006-01-10 | 2009-12-17 | Hoveyda Amir H | Catalytic enantioselective silylations of substrates |
| DK2013835T3 (en) | 2006-03-31 | 2015-12-14 | Sunovion Pharmaceuticals Inc | Preparation of chiral amides and AMINES |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| RU2470011C2 (ru) | 2007-05-31 | 2012-12-20 | Сепракор Инк. | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов |
| PH12012500734A1 (en) | 2009-10-16 | 2012-11-26 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| SG10201406634VA (en) * | 2009-10-16 | 2014-11-27 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| KR20180015114A (ko) | 2015-03-11 | 2018-02-12 | 멜린타 테라퓨틱스, 인크. | 항미생물 화합물 및 이의 제조 및 사용 방법 |
| EP3452479A1 (en) | 2016-05-06 | 2019-03-13 | Melinta Therapeutics, Inc. | Antimicrobials and methods of making and using same |
| CN109553580B (zh) * | 2017-09-25 | 2023-08-11 | 南京长澳医药科技有限公司 | 硝基咪唑类化合物中间体及其盐的制备方法 |
| CN112442022B (zh) * | 2019-09-02 | 2022-05-20 | 承德医学院 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE200740C (enExample) | ||||
| US3706810A (en) | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
| US4692522A (en) | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
| US4668769A (en) | 1985-08-02 | 1987-05-26 | Hoover Dennis J | Oxa- and azahomocyclostatine polypeptides |
| US4720503A (en) | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| US4599198A (en) | 1985-08-02 | 1986-07-08 | Pfizer Inc. | Intermediates in polypeptide synthesis |
| FR2601368B1 (fr) | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| DE3629545A1 (de) | 1986-08-30 | 1988-03-10 | Bayer Ag | Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4751231A (en) | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
| JPH02124756A (ja) | 1988-07-27 | 1990-05-14 | Suzuki Sangyo Kk | セメンティング組成物 |
| JPH04179949A (ja) | 1990-11-15 | 1992-06-26 | Fuji Photo Film Co Ltd | 新規な色素形成カプラーおよび該カプラーを用いたハロゲン化銀カラー写真感光材料 |
| JP2668003B2 (ja) | 1992-06-12 | 1997-10-27 | ファイザー インク． | ヒトの心臓キマーゼを含むアンギオテンシンｉキマーゼに関する阻害剤 |
| ES2081747B1 (es) | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
| EP0749423B1 (en) | 1994-03-09 | 2003-06-18 | Novo Nordisk A/S | Piperidines and pyrrolidines |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| FR2723739B1 (fr) | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
| DE4445968A1 (de) | 1994-12-22 | 1996-06-27 | Bayer Ag | Verwendung von Sulfonylguanazinen |
| JP3314938B2 (ja) | 1995-06-06 | 2002-08-19 | ファイザー・インコーポレーテッド | グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体 |
| MX9709874A (es) | 1995-06-06 | 1998-03-31 | Pfizer | N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN. |
| EP1134213B1 (en) | 1995-06-06 | 2005-11-02 | Pfizer Inc. | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides |
| IL124109A (en) | 1995-09-08 | 2001-10-31 | Novo Nordisk As | Pharmaceutical composition of 2-alkylpyrrolidines for use in the manufacture of medicaments for the treatment of diabetes |
| AU2090897A (en) | 1996-02-29 | 1997-09-16 | Mikael Bols | Hydroxyhexahydropyridazines |
| WO1997045425A1 (en) | 1996-05-27 | 1997-12-04 | Fujisawa Pharmaceutical Co., Ltd. | New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
| US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| WO1998027108A2 (en) | 1996-12-16 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds and their use as nitric oxide synthase inhibitors |
| JP2001514632A (ja) | 1997-03-07 | 2001-09-11 | ノボ ノルディスク アクティーゼルスカブ | 新規ヘテロサイクリック化合物 |
| EP0983239A1 (en) | 1997-05-06 | 2000-03-08 | Novo Nordisk A/S | Novel heterocyclic compounds |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
| WO2000042213A1 (en) | 1999-01-13 | 2000-07-20 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
| AU2535700A (en) | 1999-02-12 | 2000-08-29 | Novo Nordisk A/S | Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation |
| US6043091A (en) | 1999-07-19 | 2000-03-28 | Isis Pharmaceuticals Inc. | Antisense modulation of liver glycogen phosphorylase expression |
| JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
| EP1220832A1 (en) | 1999-09-29 | 2002-07-10 | Novo Nordisk A/S | Novel aromatic compounds |
| DK1088824T3 (da) * | 1999-09-30 | 2004-04-13 | Pfizer Prod Inc | Bicykliske pyrrolylamider som glycogen phosphorylase inhibitorer |
| SE9903998D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
| ES2259617T3 (es) | 1999-11-05 | 2006-10-16 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Compuestos heterociclicos y su aplicacion como medicamentos. |
| ES2487897T3 (es) | 2000-01-21 | 2014-08-25 | Novartis Ag | Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos |
| CO5271699A1 (es) | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| US6555569B2 (en) | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| AR027656A1 (es) | 2000-03-16 | 2003-04-09 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
| US20010053791A1 (en) | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
| EP1136071A3 (en) | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
| ES2218338T3 (es) | 2000-04-13 | 2004-11-16 | Pfizer Products Inc. | Efecto sinergico de gliburida y milrinona. |
| AU2001262318B2 (en) | 2000-06-09 | 2005-09-08 | Sanofi-Aventis Deutschland Gmbh | Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament |
| US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| US20020028826A1 (en) | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| IL144507A0 (en) | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| GB0021831D0 (en) | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| AU2001288110A1 (en) | 2000-09-27 | 2002-04-08 | Takeda Chemical Industries Ltd. | Spiro compounds |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| US6933317B2 (en) | 2000-11-01 | 2005-08-23 | Shionogi & Co. Ltd. | PGD2 receptor antagonistic pharmaceutical compositions |
| US20030147866A1 (en) | 2001-04-04 | 2003-08-07 | Nicolette Charles A. | Novel BGP compounds for therapy and diagnosis and methods for using same |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| EP1542712A2 (en) | 2001-06-01 | 2005-06-22 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| WO2003037864A1 (en) | 2001-10-29 | 2003-05-08 | Japan Tobacco Inc. | Indole compound and medicinal use thereof |
| EP1451156A4 (en) | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOCHINOLINVERBINDUNGEN |
| MXPA03000966A (es) | 2002-02-28 | 2003-09-04 | Pfizer Prod Inc | Agentes antidiabeticos. |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| AU2003227360A1 (en) | 2002-04-25 | 2003-11-10 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amide derivatives or salts thereof |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| MXPA05004968A (es) | 2002-11-07 | 2005-08-02 | Pfizer Prod Inc | N-(indol-z-carbonil)amidas como agentes anti-diabeticos. |
| US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| JP2004196702A (ja) | 2002-12-18 | 2004-07-15 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド誘導体又はその塩 |
| US7501440B2 (en) | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
| CA2522225A1 (en) | 2003-04-17 | 2004-10-28 | Pfizer Products Inc. | Carboxamide derivatives as anti-diabetic agents |
| MXPA05011702A (es) | 2003-04-30 | 2006-01-23 | Pfizer Prod Inc | Agentes antidiabeticos. |
| WO2004113345A1 (ja) | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | 縮合ピロール化合物及びその医薬用途 |
| GB0318464D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0318463D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0319690D0 (en) | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| GB0319759D0 (en) | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| WO2005020986A1 (en) | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity |
| WO2005020985A1 (en) | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity |
| GB0320422D0 (en) | 2003-08-30 | 2003-10-01 | Astrazeneca Ab | Chemical compounds |
-
2002
- 2002-03-06 GB GBGB0205165.4A patent/GB0205165D0/en not_active Ceased
-
2003
- 2003-03-04 CN CNB038102145A patent/CN100384852C/zh not_active Expired - Fee Related
- 2003-03-04 MX MXPA04008614A patent/MXPA04008614A/es active IP Right Grant
- 2003-03-04 KR KR10-2004-7013863A patent/KR20040096661A/ko not_active Ceased
- 2003-03-04 BR BR0308146-0A patent/BR0308146A/pt not_active IP Right Cessation
- 2003-03-04 WO PCT/GB2003/000877 patent/WO2003074532A1/en not_active Ceased
- 2003-03-04 IL IL16380303A patent/IL163803A0/xx unknown
- 2003-03-04 NZ NZ534990A patent/NZ534990A/en unknown
- 2003-03-04 JP JP2003573000A patent/JP2005526058A/ja not_active Withdrawn
- 2003-03-04 EP EP03709947A patent/EP1483270A1/en not_active Withdrawn
- 2003-03-04 US US10/506,741 patent/US7129249B2/en not_active Expired - Fee Related
- 2003-03-04 AU AU2003214377A patent/AU2003214377A1/en not_active Abandoned
- 2003-03-04 CA CA002477667A patent/CA2477667A1/en not_active Abandoned
- 2003-03-04 PL PL03372973A patent/PL372973A1/xx not_active Application Discontinuation
- 2003-03-05 TW TW092104650A patent/TW200305412A/zh unknown
- 2003-03-06 AR ARP030100768A patent/AR038888A1/es unknown
-
2004
- 2004-08-23 ZA ZA200406679A patent/ZA200406679B/en unknown
- 2004-09-14 NO NO20043852A patent/NO20043852L/no not_active Application Discontinuation
-
2006
- 2006-08-08 US US11/463,144 patent/US7276517B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003214377A1 (en) | 2003-09-16 |
| IL163803A0 (en) | 2005-12-18 |
| US20070043069A1 (en) | 2007-02-22 |
| TW200305412A (en) | 2003-11-01 |
| WO2003074532A1 (en) | 2003-09-12 |
| MXPA04008614A (es) | 2004-12-06 |
| KR20040096661A (ko) | 2004-11-16 |
| AR038888A1 (es) | 2005-02-02 |
| PL372973A1 (en) | 2005-08-08 |
| GB0205165D0 (en) | 2002-04-17 |
| NO20043852L (no) | 2004-09-14 |
| NZ534990A (en) | 2006-02-24 |
| US20050131015A1 (en) | 2005-06-16 |
| US7129249B2 (en) | 2006-10-31 |
| JP2005526058A (ja) | 2005-09-02 |
| CN100384852C (zh) | 2008-04-30 |
| CA2477667A1 (en) | 2003-09-12 |
| CN1653070A (zh) | 2005-08-10 |
| US7276517B2 (en) | 2007-10-02 |
| EP1483270A1 (en) | 2004-12-08 |
| ZA200406679B (en) | 2005-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308146A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BR0308145A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BR0308144A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BRPI0614168A2 (pt) | Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto | |
| BRPI0409938A (pt) | derivados de azetidinacarboxamida e seu uso em terapia | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| BRPI0517423A (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto | |
| BRPI0515412A (pt) | composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica | |
| BR0308653A (pt) | Cristais de derivado de benzeno de glicopiranosiloxibenzila | |
| BRPI0413233A (pt) | novos compostos | |
| BR0317268A (pt) | Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos | |
| BRPI0416004A (pt) | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo | |
| DE60017115D1 (de) | Amid-derivate und deren medizinische verwendung | |
| BRPI0413232B8 (pt) | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto | |
| BRPI0309534B8 (pt) | derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica | |
| WO2008002596A3 (en) | Adenosine a2a receptor antagonists | |
| NO986055L (no) | Nye heterocykliske forbindelser, deres fremstilling, farmas°ytiske preparater inneholdende forbindelsene og deres anvendelse ved behandling av diabetes og beslektede sykdommer | |
| BR122012009489B8 (pt) | processo para produzir 2-etóxi-1-{[2-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso | |
| BR0111754A (pt) | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica | |
| BR9916590A (pt) | Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, método para a produção de um efeito anti-câncer em um animal de sangue quente, uso do derivado de pirimidina, e, composição farmacêutica | |
| BR0312957A (pt) | Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento | |
| BR0214989A (pt) | Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto | |
| BRPI0409110A (pt) | derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer | |
| AR019365A1 (es) | Compuesto de 1-piperidin-3-fenil-butil-naftamida, proceso para prepararlo, composicion farmaceutica y uso para fabricar un medicamento util para eltratamiento de una enfermedad por antagonistas de taquicininas neuropeptidicas endogenas | |
| DE602008001725D1 (de) | 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011. |